Abstract
Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication. Several therapies are presently in development. Taribavirin hydrochloride (Viramidine®, Valeant Pharmaceutical International, Singapore), a ribavirin prodrug, has shown promise, although the rate of sustained virologic response with this agent has been disappointing. The next generation of antivirals will consist of protease and polymerase inhibitors, a number of which are undergoing investigation, initially as monotherapy and subsequently in combination with pegylated interferon and ribavirin. Challenges include the prevention of recurrent HCV infection in liver-transplant recipients and development of a safe and effective HCV vaccine.
| Original language | English |
|---|---|
| Journal | Nature Clinical Practice Gastroenterology and Hepatology |
| Volume | 4 |
| Issue number | SUPPL. 1 |
| DOIs | |
| State | Published - Jan 1 2007 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Cite this
Emerging strategies for pegylated interferon combination therapy. / Schiff, Eugene R.
In: Nature Clinical Practice Gastroenterology and Hepatology, Vol. 4, No. SUPPL. 1, 01.01.2007.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Emerging strategies for pegylated interferon combination therapy
AU - Schiff, Eugene R
PY - 2007/1/1
Y1 - 2007/1/1
N2 - Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication. Several therapies are presently in development. Taribavirin hydrochloride (Viramidine®, Valeant Pharmaceutical International, Singapore), a ribavirin prodrug, has shown promise, although the rate of sustained virologic response with this agent has been disappointing. The next generation of antivirals will consist of protease and polymerase inhibitors, a number of which are undergoing investigation, initially as monotherapy and subsequently in combination with pegylated interferon and ribavirin. Challenges include the prevention of recurrent HCV infection in liver-transplant recipients and development of a safe and effective HCV vaccine.
AB - Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication. Several therapies are presently in development. Taribavirin hydrochloride (Viramidine®, Valeant Pharmaceutical International, Singapore), a ribavirin prodrug, has shown promise, although the rate of sustained virologic response with this agent has been disappointing. The next generation of antivirals will consist of protease and polymerase inhibitors, a number of which are undergoing investigation, initially as monotherapy and subsequently in combination with pegylated interferon and ribavirin. Challenges include the prevention of recurrent HCV infection in liver-transplant recipients and development of a safe and effective HCV vaccine.
UR - http://www.scopus.com/inward/record.url?scp=33846410735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846410735&partnerID=8YFLogxK
U2 - 10.1038/ncpgasthep0691
DO - 10.1038/ncpgasthep0691
M3 - Article
C2 - 17235281
AN - SCOPUS:33846410735
VL - 4
JO - Nature Reviews Gastroenterology and Hepatology
JF - Nature Reviews Gastroenterology and Hepatology
SN - 1759-5045
IS - SUPPL. 1
ER -